Opsonic activity assessment of human intravenous immunoglobulin preparations against drug-resistant bacteria

Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
Yasuo OnoYukihisa Miyazawa

Abstract

We have used the ability of opsonized bacteria to stimulate luminol-enhanced chemiluminescence (CL) of human polymorphonuclear leukocytes (PMN) to examine the opsonic capabilities of commercially available human intravenous immunoglobulin (i.v.Ig) preparations. The method was tested against 14 strains of drug-resistant gram-positive bacteria (including methicillin-resistant Staphylococcus aureus, hetero-vancomycin-resistant S. aureus, vancomycin-resistant enterococci, penicillin-resistant Streptococcus pneumoniae), and 23 strains of gram-negative bacteria (including extended-spectrum beta-lactamase-producing bacteria, metallo-beta-lactamase-producing bacteria, beta-lactamase-negative ampicillin-resistant Haemophilus influenzae). An Fc-intact i.v.Ig preparation treated with polyethylene glycol (PEG) was evaluated for opsonization effectiveness against these bacteria in vitro. The opsonization of these organisms was enhanced by an Fc-intact i.v.Ig, and the opsonic activity was dose dependent. A pepsin-treated i.v.Ig preparation exhibited poor opsonic activity for all bacteria tested. These results suggest that Fc-intact i.v.Ig, which augments opsonic activity against various drug-resistant bacteria, will be a useful addition to t...Continue Reading

References

Jan 1, 1977·Annual Review of Biochemistry·S C SilversteinZ A Cohn
Jul 1, 1990·Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases·Y OnoO Kunii
Nov 1, 1987·Journal of Clinical Immunology·S Bender, S Hetherington
Aug 1, 1986·Journal of Clinical Pathology·L A Clark, C S Easmon
Mar 30, 1984·The American Journal of Medicine·H R HillA O Shigeoka
Dec 1, 1994·The Pediatric Infectious Disease Journal·L E WeismanG W Fischer
Sep 1, 1994·The Journal of Infectious Diseases·G VitharssonH Valdimarsson
Apr 4, 2003·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Kenji SuzukiShunkichi Baba
Nov 19, 2003·Scandinavian Journal of Infectious Diseases·John Turnidge
Dec 24, 2003·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Kimiko Ubukata

❮ Previous
Next ❯

Citations

Mar 28, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·N FaragM El-Azizi
Oct 26, 2016·Transplant Infectious Disease : an Official Journal of the Transplantation Society·Elizabeth SarmientoJavier Carbone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.